Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Jefferies London Healthcare Conference 2024
30 slides from Sutro Biopharma's conference presentation, Nov 21, 2024
Slide 1: Jefferies London Healthcare Conference
Jefferies London Healthcare Conference November 21, 2024 Sutro Biopharma NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Next-Generation ADCs and Biologics, Transforming Science for Patients
3 Next-Generation ADCs and Biologics, Transforming Science for Patients Luvelta Luvelta pipeline-in-a-drug potential with two registrational trials ongoing and multiple follow-on opportunities Proven Cell Free Discovery and Manufacturing Pipeline Platform Driving Three Emerging pipeline of next-gene
Slide 4: Sutro Pipeline Drives Broad Potential with Significant Near- and Long-term Opportunities
Sutro Pipeline Drives Broad Potential with Significant Near- and Long-term Opportunities Luvelta Lead Opportunity: Next-Generation ADCs: Additional Luvelta Opportunities Ovarian Cancer (Fast Track Designation) Features Not Possible with Other Platforms Registrational study underway CBF/GLIS2 Pediatr
Slide 5: Well Capitalized with Strong Business Development Track Record
5 Well Capitalized with Strong Business Development Track Record (1) in cash, cash equivalents & (2) Funding generated from our ~$388M marketable securities ~$975M collaborators Partnerships Provide over $2 Billion Potential Future Milestones plus Royalties Phase 2/3 vaccines Blackstone purchase of
Slide 6: STRO-002 Luveltamab Tazevibulin (Luvelta)
STRO-002 Luveltamab Tazevibulin (Luvelta) 6 NON CONFIDENTIAL
Slide 7: Luvelta: Deliberate Design + Development Enables Pipeline-in-a-Drug Opportunity
Luvelta: Deliberate Design + Development Enables Pipeline-in-a-Drug Opportunity Precisely Designed ADC to Expand Potential to Address Multiple FRα Expressing Cancers, Patient Access Including those with Low Expression Levels Hemiasterlin payload • Promising clinical activity in all indications evalu
Slide 8: Significant Opportunities, Initially in Ovarian and Expanding to Additional FRα Expressing Cancers
Significant Opportunities, Initially in Ovarian and Expanding to Additional FRα Expressing Cancers Luvelta Potentially Doubles the Estimated Annual Incidence in FRα-Expressing Patient Populations Addressable PROC Patients (U.S., Europe and Japan) Percent of Ovarian Cancer Patients Eligible for Thera
Slide 9: Opportunity to be First Therapy for Broad PROC Patient Population
Opportunity to be First Therapy for Broad PROC Patient Population Treatment Eligibility is Driven Comparison of Potential Luvelta Population by FRα Biomarker Test with Approved ADC Population Luvelta has demonstrated clinical activity in PROC patients TPS Staining Intensity 1+ Staining Intensity 2+
Slide 10: Registrational Strategy Supported by Clinical Data from ~100 Patients
Registrational Strategy Supported by Clinical Data from ~100 Patients Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=92 Evaluable) 20% 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg -30% Partial response Ovarian Cancer Patients Total (N = 99) Platinum Sensitive 21 (21
Slide 11: Use of Prophylactic G-CSF on Day 8 with Higher 5.2mg/kg Dose Demonstrated Effective Reduction of Neutropenia
Use of Prophylactic G-CSF on Day 8 with Higher 5.2mg/kg Dose Demonstrated Effective Reduction of Neutropenia Maximum Reduction in Tumor Grade 3+ Neutropenia Cohort A1 vs. Cohort with G-CSF2 Target Lesions (N=16) 20% Cycle 1 Cycle 1+2 100% 80% 71.4% 66.7% Percent Patients 60% 90.6% 73.7% -30% Reducti
Slide 12: REFRαME-O1: Registration-directed Study for patients with PROC
REFRαME-O1: Registration-directed Study for patients with PROC • Part 1 – Fully enrolled (50 patients) in April 2024; patients now in follow up • Part 2 – Enrolling patients Phase 2: Phase 3: Eligibility Key Endpoints Dose Finding Randomized Trial • Platinum Resistant Ovarian Dose A: • Final analysi
Slide 13: REFRαME-P1: Addressing Unmet Patient Need + Accelerating PROC
REFRαME-P1: Addressing Unmet Patient Need + Accelerating PROC • Pediatric RAM AML – devastating disease impacting infants and toddlers: overall survival of 15-30% • Regulatory submission requirements in U.S. and Europe may be applicable for PROC submissions • Potential to receive priority review vou
Slide 14: Luvelta Plus Bevacizumab Combination Potentially Supports All-Comers Approach
Luvelta Plus Bevacizumab Combination Potentially Supports All-Comers Approach Phase 1b Response Data (Presented at ESMO 2024)1 Phase 2 Expansion Cohort All Patients 4.3kg/mg Prior Bev FRαTPS • 23 patients enrolled to-date, (all doses) N=9 Naïve Treated <25% ≥25% including PSOC & PROC N=17 N=8 N=9 N=
Slide 15: Luvelta Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile in Lower FRα Expression Tumors
Luvelta Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and/or Variable FRα Expression Tumors Endometrial RAM AML1 NSCLC N = 17 N = 25 Preclinical Evidence of anti-tumor activity Meaningful clinical responses, including complete Single dose and combination with PD-
Slide 16: FRα is Broadly Expressed Across Multiple Indications
16 mRNA expression level (RMA, log2) 4 6 8 10 12 endometrium (27) ovary (51) kidney (34) bile duct (8) colorectal (61) breast (58) pancreas (44) stomach (38) esophagus (25) lung_NSC (131) other (15) upper_aerodigestive (32) urinary tract (27) chondrosarcoma (4) glioma (62) liver (28) medulloblastoma
Slide 17: Advancing Science to Deliver Three INDs Over the Next Three Years
Advancing Science to Deliver Three INDs Over the Next Three Years 17 NON CONFIDENTIAL
Slide 18: Enhancing ADCs Inside and Outside the Tumor With Sutro's Platform Technologies
Enhancing ADCs Inside and Outside the Tumor With Sutro’s Platform Technologies Leads to a Higher Therapeutic Index Key Sutro Technologies to Improve ADCs Outside the Tumor Linker & payload design MTD ADC Click chemistry Site specific conjugation MTD ADC Antibody engineering TI TI MED ADC Focused R&D
Slide 19: Comparison of Topo1i ADC Platforms (Selected)
Comparison of Topo1i ADC Platforms (Selected) Beta-Glu ADC2/ iADC/ Site HT DAR>8 Fc Silent Bispecific Linker Dual LPs iSAC Specific Screening Abbvie AstraZeneca Daiichi Sankyo Dualitybio Genequantum Genmab Gilead Hansoh Hengrui Kelun Lilly Medilink Merck KGaA Pfizer LP – linker payloads; iSAC – immu
Slide 20: STRO-004 is a Next Generation ADC with Enhanced Therapeutic Potential
STRO-004 is a Next Generation ADC with Enhanced Therapeutic Potential Tissue Factor-targeting ADC, featuring a DAR8 exatecan payload and site-specific linker design TF presents an opportunity for STRO-004 is optimally designed for pan-tumor targeting broad therapeutic benefit • Clinical validation o
Slide 21: STRO-004 DAR8 Exatecan Achieves Sustained Tumor Regressions in Xenograft Models
STRO-004 DAR8 Exatecan Achieves Sustained Tumor Regressions in Xenograft Models of NSCLC and HNSCC at Low Doses Lung (TF+++) Head and Neck (TF++) H1975 Growth Curves Detroit562 Growth Curves 1500 1500 (mm3)3) (mm33)) 1250 1250 Volume(mm volume (mm 1000 1000 Tumor Volume TumorVolume 750 750 500 500 T
Slide 22: STRO-004 Widens the Therapeutic Window Compared to First Generation TF ADCs
STRO-004 Widens the Therapeutic Window Compared to First Generation TF ADCs Increased Tolerability Leads to Enhanced Drug Exposure Cmax AUClast MTD ADC 170,880 MTD ADC 1,350 TI TI ADC (h*ug/mL) ADC (ug/mL) MED ADC 50x MED ADC TF-MMAE STRO-004 81.1 HNSTD ~ 5 mg/kg* HNSTD ~ 50 mg/kg# 3,440 STR0-004 Ap
Slide 23: Our Focused R&D Strategy: Make ADCs Better Inside the Tumor with Dual-Payloads
Our Focused R&D Strategy: Make ADCs Better Inside the Tumor with Dual-Payloads Multiple different dual-payload ADCs Best-in-class platform potential to optimize dual-payload ADCs Overcome resistance in clinic 23 NON CONFIDENTIAL
Slide 24: Improved In Vitro Activity of Dual-Payload ADC (Topo1i + anti-Tubulin)
100 100 100 Improved In Vitro Activity of Dual-Payload ADC (Topo1i + anti-Tubulin) % viability % viability % viability 50 50 50 SKBR3 HCC1954 0 KPL4 0 HCC1419 0 0.001 0.01 0.1 1 10 100 1000 0.001 0.01 0.1 1 10 100 1000 0.001 0. nM nM SKBR3 SKBR3SKBR3 HCC1954 HCC1954 HCC1954 KPL4 KPL4 KPL4 NCIN87 HCC
Slide 25: Dual-Payload Topo1i + PARPi ADC Shows Increased Activity Compared to Topo1i ADC
Dual-Payload Topo1i + PARPi ADC Shows Increased Activity Compared to Topo1i ADC MC38-hTF MC38-hTF in vitro potency in vivo anti-tumor activity DAR2 PARPi ADC Vehicle (PBS) DAR4 Topo1i ADC 5 mg/kg DAR4 Topo1i ADC DAR4 Topo1i + DAR2 PARPi ADC2 5 mg/kg DAR4 Topo1i + DAR2 PARPi ADC2 PBS – phosphate buff
Slide 26: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)
New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Strategic iADC Collaboration • Combining a cytotoxin and immune modulator gives potential to: • Work alone by pushing on the gas of the immune system and priming new populations of immune cells • Synergize with other immu
Slide 27: Novel Mechanism of Action Differentiates iADC from Other Immunotherapies
Novel Mechanism of Action Differentiates iADC from Other Immunotherapies Sutro iADCs bridge innate and adaptive immunity to provide broad Sutro STING / PD-1 / CAR-T protection in a single molecule ISAC Vaccine iADC TLR PDL-1 Cells Molecule Targeted and Chemo Mixed ADC Ab Biologic Biologic homogeneou
Slide 28: Express Cell-free Platform - Commercial GMP Scale Enabled in 2024
28 Express Cell-free Platform - Commercial GMP Scale Enabled in 2024 Approach / Feature Advantages Results • Stockpiled cell-free extract used to create a Cell-free extract and platform wide variety of proteins elements produced separately • Eliminates cell line development and cell Fully folded, ac
Slide 29: Potential for Broad Patients Benefits with Significant Upcoming Milestones
Potential for Broad Patients Benefits with Significant Upcoming Milestones WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER SUTRO-LED PROGRAMS Ovarian Cancer Ovarian Cancer Luveltamab (bevacizumab combo) (Greater Chin
Slide 30: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Anne Borgman, MD Barbara Leyman, PhD Ed Albini, MBA Chief Executive Officer and Chief Medical Officer Chief Business Development Officer Chief Financial Officer Member of the Board of Directors Hans-Peter Gerber, PhD Jane Chung, RPh Linda Fitzpatrick Ve
Sutro Biopharma — Jefferies London Healthcare Conference 2024 on 6ix